The Market Reports

Synopsis
The global market for LFA-based Cardiac was estimated to be worth US$ 4181 million in 2024 and is forecast to a readjusted size of US$ 6210 million by 2031 with a CAGR of 5.6% during the forecast period 2025-2031.
Lateral flow cardiac markers are a rapid detection tool based on lateral flow immunochromatography technology, which is used to qualitatively or quantitatively detect specific cardiac biomarkers in the blood (such as troponin I/T, myoglobin, BNP, etc.). The principle is to form a visual detection line on the test strip through antigen-antibody reaction, so as to quickly judge abnormal cardiac function or myocardial damage. This technology has the advantages of convenience, rapidity (results in 15-30 minutes), low cost, and no need for complex equipment. It is widely used in emergency, primary care, home self-testing and other scenarios.
Market drivers:
Disease demand growth:
Cardiovascular disease is the world's leading cause of death, with a large and growing patient base. China has more than 330 million cardiovascular disease patients, and there is an urgent need for early screening and immediate diagnosis.
Acute myocardial infarction, heart failure and other acute diseases require rapid testing (such as the demand for troponin immediate testing in chest pain centers), and lateral flow technology can shorten the diagnosis time and improve prognosis.
Policy promotion:
Tiered diagnosis and treatment: Policies guide the sinking of high-quality medical resources, and primary medical institutions (such as community hospitals and township health centers) need to be equipped with POCT (point-of-care testing) equipment. Lateral flow cardiac markers are the first choice because of their simple operation and low cost.
Medical insurance coverage: Some cardiac marker tests are included in medical insurance, reducing the burden on patients and improving the accessibility of testing.
Technology iteration:
Sensitivity improvement: The application of nanomaterials (such as gold nanoparticles) improves detection sensitivity and can detect low-concentration markers (such as high-sensitivity troponin).
Multi-indicator joint detection: The same test strip realizes the joint detection of multiple markers (such as troponin + BNP + D-dimer), improving diagnostic efficiency.
Intelligence: Combined with mobile phone APP or portable reader, the results can be automatically transmitted and interpreted to reduce human errors.
Application scenario expansion:
Pre-hospital emergency: rapid screening at ambulance and emergency scene, auxiliary decision-making (such as whether to transfer directly to the catheterization room).
Home monitoring: patients with chronic heart failure can self-test BNP at home and adjust drug dosage in time.
Physical examination screening: early cardiac function assessment for high-risk groups (such as patients with hypertension and diabetes).
Market trend:
Domestic substitution: domestic companies (such as Wondfo Biotech and Mindray Biotech) have made technological breakthroughs, breaking the import monopoly and reducing costs.
Standardized development: industry standards are gradually improved, promoting the transformation of product homogeneity to differentiated competition (such as specific marker detection and personalized services).
The lateral flow cardiac marker market is driven by disease demand, policy promotion, and technological upgrading. In the future, it will continue to develop in the direction of rapidity, multi-indicators, and intelligence, and become an important tool for the diagnosis and treatment of cardiovascular diseases.
This report aims to provide a comprehensive presentation of the global market for LFA-based Cardiac, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of LFA-based Cardiac by region & country, by Type, and by Application.
The LFA-based Cardiac market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding LFA-based Cardiac.
Market Segmentation
By Company
Roche
Abbott
Siemens
Danaher
Bio-Rad Laboratories
BioMérieux
Thermo Fisher
Ortho Clinical Diagnostics
LSI Medience Corporation
Randox laboratories
Wondfo Biotech
EasyDiagnosis Biomedicine
Segment by Type
Troponin I
Troponin T
CK-MB
Myoglobin
Others
Segment by Application
Laboratory Testing
Point-of-care Testing
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of LFA-based Cardiac company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of LFA-based Cardiac in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of LFA-based Cardiac in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Index